Compare LESL & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LESL | RNAZ |
|---|---|---|
| Founded | 1963 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3M | 8.0M |
| IPO Year | 2020 | 2021 |
| Metric | LESL | RNAZ |
|---|---|---|
| Price | $1.79 | $8.89 |
| Analyst Decision | Hold | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $2.54 | N/A |
| AVG Volume (30 Days) | ★ 161.0K | 5.2K |
| Earning Date | 05-07-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,241,915,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.62 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.27 | $0.27 |
| 52 Week High | $6.92 | $20.99 |
| Indicator | LESL | RNAZ |
|---|---|---|
| Relative Strength Index (RSI) | 67.65 | 49.72 |
| Support Level | $1.51 | $8.29 |
| Resistance Level | $1.99 | $9.44 |
| Average True Range (ATR) | 0.17 | 0.57 |
| MACD | 0.06 | 0.06 |
| Stochastic Oscillator | 69.07 | 41.53 |
Leslies Inc is a direct-to-consumer pool and spa care brand offering a comprehensive assortment of products, including chemicals, equipment and parts, cleaning and maintenance equipment, and safety, recreational, and fitness-related products. The company serves residential pool, residential spa, professional pool, and commercial pool consumers and markets its products through over 1,000 company-operated locations in 39 states and e-commerce websites, operating only in the United States. It operates mainly in the pool and spa aftermarket industry and offers regularly purchased, non-discretionary maintenance items, along with installation and repair services for pool and spa equipment.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.